# TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

> **NCT04013802** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 47 (estimated)

## Conditions studied

- Viral Infection

## Interventions

- **BIOLOGICAL:** HLA-matched VSTs

## Key facts

- **NCT ID:** NCT04013802
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-08
- **Primary completion:** 2026-05-01
- **Final completion:** 2031-05-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04013802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04013802, "TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04013802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*